Silence Therapeutics (SLN) Operating Leases (2023 - 2026)
Silence Therapeutics (SLN) reported Operating Leases of $43000.0 for Q1 2026, down 39.44% sequentially from $71000.0 in Q4 2025.
Silence Therapeutics (SLN) Operating Leases (2023 - 2026) Analysis & Trends
Silence Therapeutics (SLN) has 3 years of Operating Leases data on file, last reported at $43000.0 in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $43000.0; the trailing twelve-month figure through Mar 2026 stood at $43000.0 (changed N/A YoY), and the FY2025 full-year result was $71000.0, changed N/A from the prior year.
- Operating Leases fell to $43000.0 in Q1 2026, from $71000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $115427.1 in Q4 2023 to a low of $43000.0 in Q1 2026.
- A 3-year average of $81606.8 and a median of $84000.0 in 2025 frame the typical range for Operating Leases.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Silence Therapeutics | 1.62 Bn | 1.49 Bn | 411,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Dec 31, 2023 | 115,427.13 |